Acrivon therapeutics to present at the piper sandler annual healthcare conference

Watertown, mass., nov. 21, 2023 (globe newswire) -- acrivon therapeutics, inc. (“acrivon” or “acrivon therapeutics”) (nasdaq: acrv), a clinical stage biopharmaceutical company developing precision oncology medicines that it matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proprietary proteomics-based patient responder identification platform, acrivon predictive precision proteomics or ap3, today announced the company's president and chief executive officer, peter blume-jensen, m.d., ph.d., will participate in a fireside chat on tuesday, november 28, 2023 at 8:30 a.m. et at the piper sandler 35th annual healthcare conference in new york, ny.
ACRV Ratings Summary
ACRV Quant Ranking